2024
No Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of a Next Generation Prodrug Troriluzole (P4-4.014)
Bertz R, Rozakis R, Donohue M, Sevinsky H, Awsare B, Kaplita S, Hussey E, Qureshi I, Coric V. No Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of a Next Generation Prodrug Troriluzole (P4-4.014). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000206134.Peer-Reviewed Original ResearchEffect of hepatic impairmentHepatic impairment
2020
Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment (2126)
Ivans A, Stringfellow J, Coric V, Croop R. Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment (2126). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2126.Peer-Reviewed Original Research